SCHEMBL23247761

SCHEMBL23247761

C=C1c2c(Cl)ccc(O)c2C(O)=C2C(=O)[C@]3(O)C(O)=C(C(N)=O)C(=O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 12/20 0.78
KDM4E B2RXH2 10/20 0.78
USP2 O75604 9/20 0.78
RECQL P46063 8/20 0.78
HSD17B10 Q99714 8/20 0.78
HPGD P15428 8/20 0.78
MEN1 O00255 7/20 0.78
KMT2A Q03164 7/20 0.78
THRB P10828 6/20 0.78
MAPT P10636 6/20 0.78
ALDH1A1 P00352 6/20 0.78
L3MBTL1 Q9Y468 6/20 0.78
LMNA P02545 3/20 0.78
CASP1 P29466 1/20 0.78
CASP7 P55210 1/20 0.78
SMN1; SMN2 Q16637 1/20 0.78
NR1I2 O75469 2/20 0.75
MC4R P32245 1/20 0.75
SIRT5 Q9NXA8 1/20 0.75
POLB P06746 3/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29487299 1.00 TDP1 (0.78) TDP1KDM4EUSP2RECQLHSD17B10
Sulfosalicylic SCHEMBL29674900 0.89 TDP1 (1.00) TDP1KDM4EUSP2RECQLHSD17B10
SCHEMBL19555132 0.86 TDP1 (1.00) TDP1KDM4EUSP2RECQLHSD17B10
SCHEMBL26628251 0.86 TDP1 (1.00) TDP1KDM4EUSP2RECQLHSD17B10
SCHEMBL29537520 0.86 TDP1 (1.00) TDP1KDM4EUSP2RECQLHSD17B10
SCHEMBL30567156 0.86 TDP1 (1.00) TDP1KDM4EUSP2RECQLHSD17B10
SCHEMBL26597994 0.86 TDP1 (1.00) TDP1KDM4EUSP2RECQLHSD17B10
SCHEMBL12841672 0.85 TDP1 (0.62) TDP1KDM4EUSP2RECQLHSD17B10
Hydrochloric Acid SCHEMBL29413670 0.85 TDP1 (1.00) TDP1KDM4EUSP2RECQLHSD17B10
SCHEMBL1650332 0.85 TDP1 (0.62) TDP1KDM4EUSP2RECQLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240197767-A1 COMBINATION OF ZIDOVUDINE WITH A TETRACYCLINE ANTIBIOTIC HELPERBY THERAPEUTICS LIMITED (GB) 2024-06-20 US disclosed
US-20230201235-A1 INHIBITION OF NIDOVIRUSES THAT ENCODE NSP15 THE UNIVERSITY OF CHICAGO (US) 2023-06-29 US disclosed
CN-114765956-A Combinations of zidovudine and tetracycline antibiotics 赫尔普百治疗有限公司 2022-07-19 CN disclosed
WO-2021074598-A1 COMBINATION OF ZIDOVUDINE WITH A TETRACYCLINE ANTIBIOTIC HELPERBY THERAPEUTICS LIMITED (GB) 2021-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230201235-A1 INHIBITION OF NIDOVIRUSES THAT ENCODE NSP15 TYMP, TYMS, ISG15 TDP1 242/4885KDM4E 2895/4885USP2 1512/4885
US-20240197767-A1 COMBINATION OF ZIDOVUDINE WITH A TETRACYCLINE ANTIBIOTIC TYMS, TYMP, DHFR TDP1 2082/4885KDM4E 1512/4885USP2 3370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.